Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching to TCbHPy after early neoadjuvant insensitivity in HR-negative/HER2-positive breast cancer
ChiCTR2600119838Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Mar 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of docetaxel, carboplatin, trastuzumab, pertuzumab and pyrotinib in breast cancer (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Tumor regression rate after 2 cycles and Total pathological complete response (pCR). Planned start Mar 2026; status: not yet recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2600119838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600119838.